302 related articles for article (PubMed ID: 25926575)
1. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
2. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
4. [New Developments in CKD-MBD. New aspects in phosphate binders].
Yokoyama K
Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
[TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
6. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
8. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
[TBL] [Abstract][Full Text] [Related]
9. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
10. CKD-MBD: impact on management of kidney disease.
Ogata H; Koiwa F; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
[TBL] [Abstract][Full Text] [Related]
11. [Kidney and bone update : the 5-year history and future of CKD-MBD. Vascular calcification in CKD patients].
Joki N; Iwasaki M
Clin Calcium; 2012 Jul; 22(7):993-9. PubMed ID: 22750931
[TBL] [Abstract][Full Text] [Related]
12. Current and potential treatment options for hyperphosphatemia.
Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
[TBL] [Abstract][Full Text] [Related]
13. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
Frazão JM; Adragão T
Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
[TBL] [Abstract][Full Text] [Related]
14. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
Omata M; Fukagawa M; Kakuta T
Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
[TBL] [Abstract][Full Text] [Related]
15. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts.
Savica V; Bellinghieri G; Monardo P; Muraca U; Santoro D
J Nephrol; 2013; 26(3):456-64. PubMed ID: 22782328
[TBL] [Abstract][Full Text] [Related]
16. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
[TBL] [Abstract][Full Text] [Related]
17. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
Brandenburg VM; Jahnen-Dechent W; Ketteler M
Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
20. Phosphate binders in CKD: bad news or good news?
Drüeke TB; Massy ZA
J Am Soc Nephrol; 2012 Aug; 23(8):1277-80. PubMed ID: 22797178
[No Abstract] [Full Text] [Related]
[Next] [New Search]
